Ribomic’s wet AMD candidate shows positive phase 1/2a topline results

A single dose of RBM-007, an oligonucleotide-based aptamer with anti-FGF2 activity, showed positive topline results in a phase 1/2a clinical trial in wet age-related macular degeneration patients, according to a press release.
RBM-007 (Ribomic) was well-tolerated and had no dose-limiting toxicities or systemic or ocular serious adverse events, and seven of nine patients treated showed evidence of RBM-007 bioactivity.
The open-label, dose escalation SUSHI study included nine subjects who had previously received anti-VEGF treatments. Subjects received a single injection of RBM-007 in three

Full Story →